Innovation Pharmaceuticals Inc (IPIX)
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company listed on OTC Markets under the symbol IPIX. The company focuses on small-molecule therapies for inflammatory diseases, cancer, dermatology, and anti-infective applications. Its lead candidate, Brilacidin, has been studied for uses including oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Innovation Pharmaceuticals has a license agreement with Alfasigma S.p.A. and a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company, formerly known as Cellceutix Corporation, adopted its current name in June 2017 and was incorporated in 2005. It is headquartered in Wakefield, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-IPIX
|
—
|
—
|
—
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
1.058 M
|
—
|
—
|
—
|
—
|
—
|
—
|